Acura Pharmaceuticals receives second patent for Limitx

PALATINE - Acura Pharmaceuticals said it has received a U.S. patent for its Limitx Technology platform.

Limitx Technology is designed to address opioid abuse via the oral route of administration. Limitx contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested.

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary Limitx, Aversion and Impede technologies. Acura markets Nexafed and Nexafed Sinus, which are pseudoephedrine containing products that utilize the Impede Technology.